Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immunogen Inc (NQ: IMGN )

14.63 -0.14 (-0.95%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 25, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Immunogen Inc

< Previous 1 2 3 4 Next >
On the Road to Halving Cancer: The 2023 Biotech Advancements Igniting Hope
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 20, 2023 – USA News Group – Earlier this year, the US White House requested over $2.8 billion in funding from Congress... 
Via FinancialNewsMedia
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen, Inc.
Via Business Wire
ImmunoGen Appoints Lauren White as Senior Vice President and Chief Financial Officer
From ImmunoGen, Inc.
Via Business Wire
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen, Inc.
Via Business Wire
ImmunoGen Announces Collaboration with Takeda to Develop and Commercialize ELAHERE® in Japan
From ImmunoGen, Inc.
Via Business Wire
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen, Inc.
Via Business Wire
ImmunoGen Announces Departure of Anna Berkenblit, Chief Medical Officer
From ImmunoGen, Inc.
Via Business Wire
ImmunoGen Reports Recent Progress and Second Quarter 2023 Financial Results
From ImmunoGen, Inc.
Via Business Wire
ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Canaccord Genuity 43rd Annual Growth Conference
From ImmunoGen, Inc.
Via Business Wire
ImmunoGen Announces Multi-Target License and Option Agreement with ImmunoBiochem to Develop Next-Generation Antibody-Drug Conjugates
From ImmunoGen, Inc.
Via Business Wire
ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2023 Operating Results
From ImmunoGen Inc.
Via Business Wire
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen, Inc.
Via Business Wire
MoonLake Immunotherapeutics Makes a Moonshot on Trials
Clinical-stage biotech MoonLake Immunotherapeutics AG (NASDAQ: MLTX) shares spiked 70% on positive clinical trial results. 
Via MarketBeat
Exposures Product Safety
ImmunoGen Stock Continues to Defy Gravity on Phase 2 Trials
ImmunoGen Inc. (NASDAQ: IMGN) is a commercial-stage biotechnology company leading in antibody-drug conjugates (ADC). ADCs are like heat-seeking missiles t 
Via MarketBeat
ImmunoGen Presents Updated Findings from CADENZA Trial of Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm at EHA 2023 Congress
From ImmunoGen Inc.
Via Business Wire
ELAHERE® Demonstrates 35% Reduction in the Risk of Disease Progression or Death Versus Chemotherapy in FRα-Positive Platinum-Resistant Ovarian Cancer
From ImmunoGen Inc.
Via Business Wire
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen, Inc.
Via Business Wire
Promising Developments Announced Ahead of 2023 ASCO Annual Meeting’s Oral Presentations
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GILD),(NASDAQ:IMGN),(NASDAQ:DAWN),(NASDAQ:LEGN) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Jefferies Healthcare Conference
From ImmunoGen, Inc.
Via Business Wire
MarketBeat Week in Review – 5/8 - 5/12
Inflation, bank woes, interest rates, and the debt ceiling led to more of the new normal for equity markets. Here are some of this week's most popular articles 
Via MarketBeat
Topics Economy Electric Vehicles
Exposures Electric Vehicles Interest Rates
ImmunoGen Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From ImmunoGen, Inc.
Via Business Wire
ImmunoGen Announces Results from the Phase 3 MIRASOL Trial Selected as Late-Breaking Presentation for ASCO 2023 Annual Meeting
From ImmunoGen, Inc.
Via Business Wire
ImmunoGen Nearly Triples on Ovarian Cancer Drug Phase 3 Results
Commercial-state biotechnology company ImmunoGen Inc. (NASDAQ: IMGN) shares more than doubled on phase 3 clinical trial results. Its ovarian cancer drug 
Via MarketBeat
ImmunoGen Announces Pricing of Upsized Public Offering of Common Stock
From ImmunoGen Inc.
Via Business Wire
ImmunoGen Announces Proposed Public Offering of Common Stock
From ImmunoGen, Inc.
Via Business Wire
ELAHERE® Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRα-Positive Platinum-Resistant Ovarian Cancer
From ImmunoGen Inc.
Via Business Wire
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen, Inc.
Via Business Wire
ImmunoGen Reports Recent Progress and First Quarter 2023 Financial Results
From ImmunoGen, Inc.
Via Business Wire
ImmunoGen Appoints Isabel Kalofonos as Senior Vice President and Chief Commercial Officer
From ImmunoGen, Inc.
Via Business Wire
ImmunoGen Announces Conference Call to Discuss Its First Quarter 2023 Operating Results
From ImmunoGen Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.